Search

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

… Tuesday, April 30, 2013 Summary Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide. Targeted therapies hold promise for the treatment of many types of cancer. But a common predicament is that in many patients

The treatment that children receive for retinoblastoma can lead to health problems later in life. A new study documents their frequency and extent.

… Monday, February 1, 2016 Summary Retinoblastoma  is a rare childhood cancer that affects the eyes. It is highly treatable but can result in long-term medical consequences. A study conducted by MSK researchers documents the type and frequency of these consequences among survivors. The results will inform

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, November 2, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Mijin Kim Named A 2023 STAT Wunderkind Mijin Kim, PhD Mijin Kim, PhD , postdoctoral fellow, has been  honored   among the 2023 STAT Wunderkinds. STAT Wunderkinds acknowledges

Membership is a widely accepted mark of excellence in science and considered one of the highest honors a scientist can receive.

… Tuesday, April 28, 2020 Two Sloan Kettering Institute (SKI) researchers have been elected to the National Academy of Sciences (NAS). Scott Keeney, PhD , a molecular biologist, and Christopher Lima, PhD , a structural biologist, join more than a dozen Memorial Sloan Kettering investigators who are already

Visible Ink at Memorial Sloan Kettering Cancer Center (MSK) is the leading — and largest — writing program of its kind. Writing promotes creativity, reduces stress, and empowers people with cancer to give voice to their stories.

… Friday, April 6, 2018 Visible Ink at Memorial Sloan Kettering Cancer Center (MSK) is the leading — and largest — writing program of its kind. Writing promotes creativity, reduces stress, and empowers people with cancer to give voice to their stories. On Monday, April 16 at 6:30 p.m. , the Kaye Playhouse

Dr. Perales was formally sworn in during the 2023 Tandem Transplantation and Cellular Therapy Meetings of ASTCT and the Center for International Blood and Marrow Transplant Research (CIBMTR) on February 18.

… Monday, February 20, 2023 Miguel-Angel Perales, MD , of Memorial Sloan Kettering Cancer Center (MSK), has been named President of The American Society for Transplantation and Cellular Therapy (ASTCT) for 2023-2024. Dr. Perales was formally sworn in during the 2023 Tandem Transplantation and Cellular

Memorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next month, the 750,000-square-foot building is the institution’s — and the city’s — largest freestanding cancer care facility. The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is a healing community dedicated to patient-centered care, made possible by a landmark donation and a pioneering vision that signifies a new era of cancer care.

… Tuesday, December 10, 2019 Memorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next month, the 750,000-square-foot

Learn why post-doctoral researcher Mijin Kim believes Memorial Sloan Kettering is an excellent choice for early career biomedical researchers, as she enjoys her recognition as a STAT Wunderkind, class of 2023.

… Tuesday, October 17, 2023 Mijin Kim, PhD, a postdoctoral researcher at Memorial Sloan Kettering Cancer Center (MSK), has been recognized with the prestigious  Wunderkind award by STAT , the well-regarded news site covering science and medicine. Each year, STAT seeks to find “the best researchers in health

Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough findings for new treatment approaches in several cancer indications at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9 to 13 in Paris. Highlights included clinically meaningful benefits for new treatment strategies in advanced bladder cancer, endometrial cancer, and renal cell carcinoma. Additionally, MSK experts shared their perspectives on previously reported groundbreaking trials of new treatment approaches in colorectal cancer and HER2-low metastatic breast cancer.

… Tuesday, October 11, 2022 Advanced Bladder Cancer: Promising Results for Enfortumab Vedotin Plus Pembrolizumab MSK has been spearheading the development and testing of antibody-drug conjugates — novel biopharmaceuticals that deliver precise payloads of anti-cancer agents directly to cancer cells — alone

During a virtual awards ceremony, MSK and the Robbins Family Foundation recognized eight distinguished MSK staff members and one team for their exemplary service. Each member was honored with the 2021 Robbins Family Award for Nursing Excellence.

… Wednesday, May 12, 2021 Elizabeth McCormick, Senior Vice President, and Chief Nursing Executive Elizabeth McCormick, Senior Vice President, and Chief Nursing Executive MSK Nurses celebrate Nurses Week, May 6-12 MSK Nurses celebrate Nurses Week, May 6-12 MSK Nurses celebrate Nurses Week, May 6-12 MSK